GP (HK)’s Two Global Innovative RDC Products Usher in a New Breakthrough, TLX591-CDx Dosed the First Patient in Japan; And TLX591 was Approved for Phase III Clinical Trials in Australia - Corporate News - News Center - Grand Pharmaceutical Group Limited Menu Search